Development of pulmonary fibrosis in fibrinogen-deficient mice

Julie A. Wilberding, Victoria A. Ploplis, Laura McLennan, Zhong Liang, Ivo Cornelissen, Matthew Feldman, Melanie E. Deford, Elliot D. Rosen, Francis J. Castellino

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

Bleomycin is an antineoplastic drug commonly used for the treatment of many carcinomas and lymphomas. Its toxic side effect on hung tissue is a major limitation to its use, with approximately 3-5% of patients affected. Although the number of affected patients is small, the damage incurred by bleomycin in these patients is often irreversible and, at times, fatal. A number of therapies have been shown to be effective in animal studies to minimize damage, but to date no "magic bullet" has been identified. Many proteins of the fibrinolytic system have been implicated as playing a role in the progression of the disease, one of which is fibrinogen (Fg) acting in the context of a fibroproliferative agent. Its presence correlates with an upregulation of plasminogen activator inhibitor-1 and tissue factor in alveolar cells surrounding the lesion area. It is believed that Fg participates in the activation and migration of fibroblasts and provides a scaffold, in the form of fibrin, for cell migration following induction of acute lung injury. To further understand the mechanism of injury following bleomycin treatment and the possible role of fibrinogen therein, mice have been generated with a targeted deletion of the gamma-chain of Fg, which resulted in the absence of detectable circulating Fg. The offsprings of Fg heterozygous mice (FG+/-) mice follow Mendelian distributions indicating no embryonic lethality with this deletion. Approximately one-half of the Fg-deficient (FG-/-) neonates exhibited bleeding episodes, approximately one-half of which were fatal. For the pulmonary fibrosis study, FG-/- mice and wildtype littermates were administered a bleomycin solution intratracheally and the disease was allowed to progress for two weeks. The mice were then sacrificed, the left lung was excised for hydroxyproline analysis, the right lung was processed for histologic profiling. Examination of trichrome stained sections, surprisingly, revealed no qualitative difference between wildtype and FG-/-animals. The extent and pattern of the deposition of collagen were also similar. These results were quantitatively confirmed by hydroxyproline analysis, which revealed equivalent increases in collagen content between wildtype and FG-/- animals when compared to appropriate saline controls. Analysis of the early acute inflammatory stage of the disease showed a difference in the neutrophil population between days three and five of the disease. These studies suggest that, although fibrinogen is not required for collagen deposition at the later stage of the disease, it may play a role in the early acute inflammation stage.

Original languageEnglish (US)
Pages (from-to)542-548
Number of pages7
JournalAnnals of the New York Academy of Sciences
Volume936
DOIs
StatePublished - Jan 1 2001

Keywords

  • Fibrinogen-deficient mice
  • Pulmonary fibrosis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Fingerprint Dive into the research topics of 'Development of pulmonary fibrosis in fibrinogen-deficient mice'. Together they form a unique fingerprint.

  • Cite this

    Wilberding, J. A., Ploplis, V. A., McLennan, L., Liang, Z., Cornelissen, I., Feldman, M., Deford, M. E., Rosen, E. D., & Castellino, F. J. (2001). Development of pulmonary fibrosis in fibrinogen-deficient mice. Annals of the New York Academy of Sciences, 936, 542-548. https://doi.org/10.1111/j.1749-6632.2001.tb03542.x